Bayer Aktienges ADR (OP:BAYRY)

7.940 +0.260 (+3.39%)

Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2025 Add to My Watchlist

Price and Volume

Volume	467,960
Open	7.900
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	7.680
Today's Range	7.830 - 7.970
52wk Range	4.790 - 8.700
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗

November 20, 2025

FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for advanced lung cancer.

Via Benzinga

U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

November 20, 2025

From Bayer

Via Business Wire

Performance

YTD	+60.7%	+60.7%
1 Month	+0.1%	+0.1%
3 Month	-4.6%	-4.6%
6 Month	+13.4%	+13.4%
1 Year	+56.0%	+56.0%

More News

Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗

November 14, 2025

Via Benzinga

Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗

November 13, 2025

Via The Motley Fool

Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗

November 12, 2025

Via Benzinga

Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science

November 10, 2025

From Bayer

Via Business Wire

KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease

November 06, 2025

From Bayer

Via Business Wire

Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause

October 24, 2025

From Bayer

Via Business Wire

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025

October 21, 2025

From Bayer

Via Business Wire

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Via Benzinga

Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest

October 07, 2025

From Bayer

Via Business Wire

One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”

October 07, 2025

From Bayer

Via Business Wire

BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease

October 07, 2025

From Bayer

Via Business Wire

Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division

September 29, 2025

From Bayer

Via Business Wire

Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025

September 25, 2025

From Bayer

Via Business Wire

Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease

September 22, 2025

From Bayer

Via Business Wire

10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign

September 15, 2025

From Bayer

Via Business Wire

Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report ↗

September 15, 2025

Via Benzinga

Gadoquatrane New Drug Application Accepted for Review by U.S. FDA

August 27, 2025

From Bayer

Via Business Wire

Monsanto Reaches Agreements in Principle to Resolve Additional PCB Cases at the Sky Valley Education Center

August 18, 2025

From Bayer

Via Business Wire

Bayer® Aspirin Introduces Aspirina to the U.S. Pain Market

August 15, 2025

From Bayer

Via Business Wire

Retail Turns Bearish On Bayer After $1.3B Kumquat Cancer Drug Deal ↗

August 12, 2025

Via Stocktwits

OTC Markets Group Announces Quarterly Index Performance and Rebalancing

August 04, 2025

From OTC Markets

Via GlobeNewswire

U.S. Current-Account Deficit Widens to $450 Billion Amid Trade Imbalances and Energy Imports

July 25, 2025

Via MarketMinute

Frequently Asked Questions

Is Bayer Aktienges ADR publicly traded?

Yes, Bayer Aktienges ADR is publicly traded.

What exchange does Bayer Aktienges ADR trade on?

Bayer Aktienges ADR trades on the OTC Traded

What is the ticker symbol for Bayer Aktienges ADR?

The ticker symbol for Bayer Aktienges ADR is BAYRY on the OTC Traded

What is the current price of Bayer Aktienges ADR?

The current price of Bayer Aktienges ADR is 7.940

When was Bayer Aktienges ADR last traded?

The last trade of Bayer Aktienges ADR was at 11/21/25 03:59 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.